A question that has puzzled oncologists and researchers alike is whether pharmacogenomic testing can truly improve clinical outcomes in oncology. Can tailoring drug therapy based on an individual's genetic variations pave the way for more effective and personalized cancer treatment strategies? In this systematic review, we delve into the existing evidence surrounding pharmacogenomic testing on clinical outcomes in oncology, shedding light on its potential benefits and limitations.
Key Takeaways:
Pharmacogenomic testing has the potential to revolutionize cancer treatment by personalizing drug therapy based on genetic variations.
Oncology research heavily relies on pharmacogenomics to develop targeted therapies and improve treatment outcomes.
Barriers to the implementation of pharmacogenomic testing in clinical practice include limited education, lack of guidelines, and concerns about cost and privacy.
Enablers for the successful implem...
_____
If you are a member of our Association, please log in below to continue reading our exclusive content.
Not a member yet? Discover the benefits of joining our network and gain access to exclusive content like this for only $29.95 per month. Learn More and Sign Up
